BACKGROUND: the management of asymptomatic primary tumor in patients with unresectable metastatic colorectal cancer remains inconsistent.
i n 2008, 1.2 million cases of colorectal cancer were newly diagnosed worldwide, and 600,000 patients died from colorectal cancer, 1 making the disease the third most common cause of cancer death. approximately 20% of patients with newly diagnosed colorectal cancer will have synchronous metastatic disease, and ≈75% to 90% will have unresectable lesions. 2 traditionally, palliative resection of the primary tumor has been performed in patients with unresectable stage iV cancer to prevent subsequent complications from intact primary tumors and to accurately stage disease. using the survey of epidemiology and end Results database, investigators reported that primary tumors were resected in 2 of every 3 patients with stage iV cancer. 2,3 however, with the remarkable development of modern systemic chemotherapy (Ctx), disease progression of both metastases and primary tumors can be controlled by systemic Ctx alone. therefore, whether primary tumors in patients with unresectable stage iV cancer should be resected is of some controversy. for those patients with a symptomatic primary tumor (obstruction, bleeding, perforation, or pain), the consensus is to resect it, but for asymptomatic patients, a consensus has not been reached. according to the national Comprehensive Cancer network guidelines, routine palliative resection of a synchronous primary lesion should be considered only if the patient has an unequivocal imminent risk of obstruction or acute significant bleeding. 4 this is because the incidence of events requiring surgical intervention in upfront Ctx cases is low, ranging from 7% to 29%, [5] [6] [7] [8] [9] and palliative surgeries delay the start of systemic Ctx. however, all of these results came from retrospective studies, and few studies have taken performance status (PS), comorbidity, or colonoscopic traversability beyond the primary tumor into account. the only prospective study conducted on this subject reported that surgeries for primary tumor symptoms occurred in 11.6% of cases. 10 the effect of primary tumor resection on survival is also unclear, and the results are awaited of 2 randomized, multi-institutional phase iii studies, SYNCHRONOUS 11 and CaiRo4, 12 that are evaluating the role of primary tumor resection in asymptomatic patients with unresectable synchronous metastatic colorectal cancer.
the aim of this study was 2-fold, to evaluate the rate of symptom-directed surgery in upfront Ctx patients and to estimate the impact of initial primary tumor resection on survival in patients with unresectable stage iV colorectal cancer and an asymptomatic primary tumor.
PATIENTS AND METHODS

Patients and Definitions
Between January 2005 and December 2011, 191 consecutive patients presented to Kyoto University Hospital, a tertiary referral hospital, with synchronous stage iV colon or rectal adenocarcinoma. most of these patients were referred by primary care providers. We retrospectively collected information on all of the eligible patients from their medical charts and targeted patients with a diagnosis of clinically unresectable colorectal cancer for cure and an asymptomatic primary tumor for analysis. "Asymptomatic" was defined as having both no subjective symptoms and no obvious evidence of objective findings, such as bowel obstruction, perforation, primary tumor-related pain, or active bleeding requiring a transfusion. the large amount of data collected for each patient included demographics, primary tumor-related symptoms, colonoscopic traversability, Ctx protocol, surgical procedure, last follow-up status, and mortality (table 1) . this study used nonidentifiable data provided by Kyoto University Hospital.
We decided the initial treatment plans (Ctx, primary tumor resection, or diversion, etc) through careful discussion by our multidisciplinary team, taking into account all of the pretreatment examination findings and the patient PS and comorbidity. The multidisciplinary team consisted of both colorectal and hepatobiliary surgeons, oncologists, gastrointestinal physicians, and radiologists. a patient was considered unresectable for cure when a complete and macroscopically curative resection of both primary and metastatic tumors was not achievable. in particular, for liver metastasis we determined whether resectability was indicated according to the following criteria: 1) the ability to maintain >30% of preoperative liver function after surgery, 2) whether vessel reconstruction was required, and 3) whether invasion of all 3 hepatic veins was suspected regardless of the number and size of metastases. the study protocol was reviewed and approved by Kyoto University hospital ethics Committee.
Statistical Analysis
Results are expressed as medians and interquartile ranges (iQRs) for continuous variables and as numbers with percentages for categorical variables. tests for continuous and categorical variables were performed using the Wilcoxon nonparametric rank-sum test and χ 2 test.
in upfront Ctx cases, we estimated the rate of symptom-directed surgery using the cumulative incidence function, accounting for competing risks (CRs) to avoid the overestimation seen in the 1 minus Kaplanmeier method. 16 in this analysis, we set up the surgical interventions that were implemented because of primary tumor-related symptoms as events of interest, and the surgical interventions caused by other reasons, conversion therapy, or death from any cause as CRs. in addition, CR regression analysis was performed to identify factors associated with surgeries for primary tumor symptoms.
overall survival proportions were calculated using the Kaplan-Meier method, 17 and differences were evaluated using the log-rank test. 18 We also estimated adjusted survival using propensity scores and the Cox proportional hazard model. 19 The factors for adjustment were age, sex, PS, comorbidity, colonoscopic traversability, CEA level, and number of metastatic organs. a p value of <0.05 on a 2-tailed test was considered statistically significant. the statistical package used was Stata 11 (StataCorp LP, College Station, TX).
RESULTS
Patient Characteristics
of 191 stage iV patients, 133 were considered unresectable at diagnosis, and, of these, 94 had no primary tumor-related symptoms at diagnosis. after excluding 6 patients who underwent a diversion enterostomy before systemic Ctx, this left 88 patients for final analysis. among these 88, 47 received Ctx without primary tumor resection as the initial treatment and were classified into the upfront Ctx group (including 1 patient who underwent an exploratory laparotomy). the remaining 41 patients underwent a primary tumor resection first and were classified into the upfront primary tumor resection group (fig. 1 ). none of these patients were found to have metastasis at the time of laparotomy or laparoscopy. the upfront Ctx group showed tendencies for the patients to be younger, to have higher Cea levels, and to have a higher proportion of colonoscope-traversable cases compared with the upfront primary tumor resection group (Table 2) . No significant differences in PS and comorbidity, which are important factors in treatment planning, were identified between the 2 groups.
CTx Protocols
the most commonly used protocol for first-line Ctx was FOLFOX in both the upfront CTx and primary tumor resection groups (63.8% and 43.9%). six patients (14.6%) in the upfront primary tumor resection group did not receive Ctx, because 2 deteriorated rapidly after the surgery and 4 refused to receive Ctx or radiotherapy. there was no significant difference in the administration of biological agents throughout follow-up between the upfront Ctx and primary tumor resection groups (52.2% and 41.5%), although there was an imbalance between the arms in rela- (1 patient). the other detailed reasons for surgical intervention included prophylactic primary tumor resection at the discretion of the treating physician (3 patients), primary tumor resection for the induction of liver specific therapy for liver-limited disease (2 patients), and nonadherence to Ctx (1 patient).
Symptom-Directed Surgery in Patients With Colonoscope-Traversable Lesions
When we focused on the patients with colonoscopetraversable lesions at diagnosis, only 3 (9.1%) of 33 patients required symptom-directed surgery.
Urgent Surgery in Asymptomatic Upfront CTx Patients
among the 18 asymptomatic upfront Ctx patients requiring surgery, 2 underwent urgent procedures. the first patient required an urgent ileostomy because of a primary tumor-related obstruction ≈1 year after starting Ctx (folfiRi). Because the patient experienced no postoperative complications, Ctx was resumed, but she died from colon cancer ≈1 year later. the second patient required an urgent partial sigmoidectomy and ileostomy because of perforation of the sigmoid colon ≈1 year after treatment started (modified FOLFOX6 with no biological agent). however, she died in the hospital from sepsis 31 days after surgery. 
Morbidity and Mortality
With regard to the safety of primary tumor resection, grade 3 to 4 postoperative complications occurred in 2 (18.2%) of 11 patients who underwent the procedure during systemic Ctx and in 8 (19.5%) of 41 patients who underwent it as first-line therapy; the difference between the groups was not significant (p = 0.92). overall postoperative in-hospital mortality carried a risk of 1.7% (1 of 60 patients) in our series.
Rate of Symptom-Directed Surgery
in the 47 patients in the upfront Ctx group, events of interest (surgeries caused by primary tumor-related symptoms) occurred in 12 patients, and competing events occurred in 28 patients after a median observation period of 11.1 months (iQR, 3.5-16.8). according to CRadjusted cumulative incidence analysis, overall 1-and 2-year rates of symptom-directed surgery were 19.1% and 26.1%. When we focused on colonoscopic traversability, 1-and 2-year rates of symptom-directed surgery were 0.0% and 9.9% in the traversable group. in the nontraversable group, 64.3% of patients required surgery within 1 year ( fig. 3 ). median time until events of interest was 15.5 months (iQR, 14.0-17.0) in the traversable group and 2.1 months (iQR, 1.3-3.1) in the nontraversable group (p = 0.01). according to multivariate CR regression analysis, only colonoscopic traversability was significantly associated with surgery for primary tumor symptoms (subhazard ratio, 7.9; p = 0.004; table 4).
Conversion Therapy
Conversion therapy was required in 9.1% (8 of 88) of all patients in this study. no cases were converted to resectable disease after an upfront primary tumor resection.
all of these patients had at least metastatic liver disease. among the 8, 4 (50%) received Ctx regimens that included biological agents before the conversion. Conversion therapy was hepatectomy in all of the patients. two patients relapsed, but all 8 were alive through follow-up. Despite the short observation periods involved, median overall survival time was 22.3 months.
Overall Survival among all 88 patients, death from any cause occurred in 67 patients; the remaining 21 patients were alive after a median follow-up period of 21.3 months (iQR, 12.2-32.9). none of the patients were lost to follow-up. fig. 4 ). After adjustment, there was no significant improvement in survival in the upfront primary tumor resection group compared with the upfront Ctx group (hR, 0.72; 95% Ci: 0.42-1.25).
DISCUSSION
this study has produced 2 main findings in relation to the management of patients with unresectable, asymptomatic stage iV colorectal cancer. first, among the upfront Ctx patients, 25.5% (12 of 47) required surgery because of primary tumor-related symptoms, and those with nontraversable lesions had an ≈8-fold higher risk for late surgical intervention than those with colonoscope-traversable lesions. second, survival analysis revealed that upfront primary tumor resection showed no significant advantage for patient survival over upfront Ctx. looking more closely at the first main finding regarding the rate of symptom-directed surgery in patients who received upfront Ctx, among those who had colonoscope-traversable lesions, only 9.1% (3 of 33) required surgery at crosssectional analysis, which is comparable to the findings of 7% to 29% in previous retrospective studies 5-9 and 11.5% in the National Surgical Adjuvant Breast and Bowel Project C-10 study. 10 moreover, in patients with colonoscope-traversable lesions, CR-adjusted cumulative incidence analysis demonstrated that the 1and 2-year rates of symptom-directed surgery were 0.0% and 9.9% but were as high as 64.3% within 1 year in the patients with nontraversable lesions. on the basis of these results, we believe that patients with nontraversable lesions require primary tumor-related surgery more frequently and earlier than those with traversable lesions. this suggestion is further supported by the significant difference in the median time until symptom-directed surgery between the 2 subgroups (p = 0.01). in addition, the result of CR regression analysis supported colonoscopic traversability as the only independent predictor of surgical intervention for primary tumor-related symptoms in asymptomatic upfront Ctx patients (subhazard ratio, 7.9; p = 0.004). therefore, colonoscopic traversability at diagnosis may be an important finding for deciding the initial strategy in asymptomatic, unresectable stage iV patients.
to the best of our knowledge, the only 1 report published on the significance of colonoscopic traversability in stage iV colorectal cancer found that colonoscopic findings did not predict bowel obstruction. 20 however, several considerations should be taken into account when interpreting the result: 1) the criteria of colonoscopic findings defined as high risk were different from those used in our study; 2) the study carried a 50% conversion proportion, considerably higher than that of current prospective studies (4.9%-9.0%) 21, 22 ; and 3) obstruction was not among the symptoms requiring late surgery, a finding that is considerably different from the 8 (80%) of 10 cases in the National Surgical Adjuvant Breast and Bowel Project C-10 study 10 and 10 (83%) of 12 cases in ours. in summary, given that 74.5% of upfront Ctx patients in our study did not develop symptoms from the intact primary tumor and were able to continue initial systemic Ctx, we recommend that primary tumor resection is not necessary for patients with unresectable, asymptomatic stage iV colorectal cancer unless they have a nontraversable lesion, in which case early primary resection should be considered. in this series, no significant difference was observed regarding treatment strategy according to primary tumor location (colon or rectum), but this factor should also be taken into consideration when deciding the initial treatment plan. in rectal cancer with peritoneal carcinomatosis especially, a diversion may be a better choice than resection.
turning now to the second main finding on survival, there are conflicting results of the effect of palliative primary tumor resection on survival in patients with unresectable stage iV colorectal cancer. to date, most retrospective studies and meta-analyses have demonstrated survival benefits associated with primary tumor resection compared with systemic Ctx alone, 23 although upfront primary tumor resection delays the initiation of systemic CTx. In our study, overall adjusted-survival analysis revealed no significant survival difference between the 2 arms. however, some caution is necessary in interpreting this survival result, because the sample size was small, and disparities in the first-line Ctx protocols existed between 2 groups (eg, no patients had Ctx with a biological agent in the upfront primary tumor resection group). furthermore, the proportion of grade 3 to 4 postoperative complications in patients undergoing primary tumor resection among the upfront Ctx group (18.2%) was comparable to that in patients undergoing upfront primary tumor resection (19.5%), both of which were on the lower end of the range reported at present (19%-30%). [5] [6] [7] 9 this may be because our definition did not include grade 1 to 2 complications, and the majority (80%) of patients underwent laparoscopic primary tumor resection. 24 late surgery is generally associated with higher postoperative mortality (10%-26%) 3, 8, 10 when compared with that after early primary tumor resection (0.0%-4.6%). [5] [6] [7] 9 in our series, 1 patient in the upfront Ctx group died 31 days after urgent late surgery because of intestinal perforation. Postoperative in-hospital mortality in patients receiving a late surgical intervention was 5.6%, which is lower than that reported previously. on the basis of our findings, we believe that there might be no need to perform preemptive primary tumor resection, and instead we recommend upfront systemic Ctx in patients with traversable lesions. for patients with nontraversable lesions, preemptive primary tumor resection should be considered, because ≈65% of them could be facing late surgery within 1 year.
The major limitations of this study are its small sample size and retrospective nature. When we calculated the number of patients needed to test the hypothesis of an hR of 0.6, based on the results of faron et al, 23 with a 2-sided α of 5% and a power of 80%, the required total sample size was estimated at 208. this sample size is approximately twice the actual number of patients in our study, indicating that our study was clearly underpowered. hence, when we discuss generalizability, these results should be viewed with caution. also, colonoscopy cannot objectively evaluate luminal obstruction caused by a tumor, thus findings are difficult to standardize among colonoscopists. moreover, the progress of a colonoscope beyond a primary tumor is basically at the discretion of a scopist. for example, if a primary tumor is in the ascending colon, an endoscopist might not try to traverse an annular one, because the proximal portion would automatically be resected by surgery. in fact, the SYNCHRONOUS and CAIRO4 trials do not include colonoscopic findings as criteria. 11, 12 Despite these drawbacks, we believe that this study provides a valuable contribution to our understanding of the effect of treatment in unresectable stage iV colorectal cancer in the absence of the results of randomized, controlled trials and prospective cohort studies.
CONCLUSION
among upfront Ctx patients with unresectable, asymptomatic stage iV colorectal cancer, most might be able to be spared palliative primary tumor resection. in addition, colonoscopic findings of nontraversable lesions at diagnosis may predict the need for late surgical intervention.
